ISDA: 4WQ6

Deposition Date 2014-10-21

Release Date 2015-02-11

Last Version Date 2023-09-27

Entry Detail

PDB ID:

4WQ6

Keywords:

Transferase/Transferase inhibitor

Title:

The crystal structure of human Nicotinamide phosphoribosyltransferase (NAMPT) in complex with N-(4-{(S)-[1-(2-methylpropyl)piperidin-4-yl]sulfinyl}benzyl)furo[2,3-c]pyridine-2-carboxamide inhibitor (compound 21)

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.72 Å

R-Value Free:

0.18

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Nicotinamide phosphoribosyltransferase
Gene (Uniprot):NAMPT
Chain IDs:A, B
Chain Length:501
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P43490 Pfam ID:PF18127, PF04095 EC:2.4.2.12

Ligand Molecules

3TQ

EDO

PO4

Primary Citation

Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.

Zak, M, Liederer, B.M, Sampath, D, Yuen, P.W, Bair, K.W, Baumeister, T, Buckmelter, A.J, Clodfelter, K.H, Cheng, E, Crocker, L, Fu, B, Han, B, Li, G, Ho, Y.C, Lin, J, Liu, X, Ly, J, O'Brien, T, Reynolds, D.J, Skelton, N, Smith, C.C, Tay, S, Wang, W, Wang, Z, Xiao, Y, Zhang, L, Zhao, G, Zheng, X, Dragovich, P.S.Show

Bioorg.Med.Chem.Lett. 25 529 541 (2015)

PMID: 25556090 DOI: 10.1016/j.bmcl.2014.12.026

Abstact

Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likely source of the TDI signal, and replacement with other bicyclic systems was found to reduce or eliminate the TDI finding. A strategy of reducing the number of aromatic rings and/or lowering cLogD7.4 was then employed to significantly improve aqueous solubility. These efforts culminated in the discovery of 42, a compound with no evidence of TDI, improved aqueous solubility, and robust efficacy in tumor xenograft studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form